The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter phase II trial of mFOLFOX6 plus bevacizumab as treatment for liver-only metastases from colorectal cancer unsuitable for upfront resection (TRICC 0808).
Hiroyuki Uetake
Honoraria - Chugai Pharma; Yakult Honsha
Research Funding - Chugai Pharma; Yakult Honsha
Masamichi Yasuno
No relevant relationships to disclose
Megumi Ishiguro
No relevant relationships to disclose
Shingo Kameoka
Honoraria - Chugai Pharma; Yakult Honsha
Yasuhiro Shimada
No relevant relationships to disclose
Keiichi Takahashi
No relevant relationships to disclose
Toshiaki Watanabe
No relevant relationships to disclose
Kei Muro
No relevant relationships to disclose
Hideo Baba
Honoraria - Chugai Pharma; Yakult Honsha
Research Funding - Chugai Pharma; Yakult Honsha
Junji Yamamoto
No relevant relationships to disclose
Nobuyuki Mizunuma
No relevant relationships to disclose
Hiroshi Tamagawa
No relevant relationships to disclose
Izumi Mochizuki
No relevant relationships to disclose
Yusuke Kinugasa
No relevant relationships to disclose
Yoshihiro Matsubara
No relevant relationships to disclose
Kenichi Sugihara
No relevant relationships to disclose